Caplin Point shares fall after USFDA OAI classification
In short
Caplin Point shares fell after the USFDA gave its Gummidipoondi facility an OAI classification. The company said it does not expect any material impact on its finances or operations from the inspection or the 10 observations, so far.
The share move shows investors were uneasy about the regulatory action even though the company sounded calm about the effect.
What the reporting says
Caplin Point shares declined after the USFDA issued an OAI classification for its Gummidipoondi facility following an inspection and 10 observations. The company said it does not expect any material impact on its financials or operations from the inspection or observations, as of yet. The market reaction reflects concern over the regulatory step despite the company’s statement.
Why it matters
Caplin Point shares fell after the USFDA issued an OAI classification for the company’s Gummidipoondi facility. The company said it does not expect any material impact on its financials or operations from the inspection or the 10 observations, as of yet. The event links a regulatory action to a negative stock reaction, while the company seeks to limit concern.